Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations for Fosamax in Pennsylvania

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medications. Within this legacy framework, audiences have been equipped with baseline knowledge about pharmaceutical benefits and routine side effects, often framed in universal terms. However, as the landscape of health information evolves, a more targeted focus becomes necessary—particularly when a widely prescribed drug intersects with specific, serious adverse outcomes. In the context of mass production and widespread distribution, the medication Fosamax (alendronate) represents a case where general health messaging must give way to a precise occupational and patient-level concern. The transition from broad health literacy to a focused inquiry involves recognizing that certain populations, including those in manufacturing or clinical settings, may face elevated exposure risks. This pivot is not about detailing disease mechanisms but about acknowledging that the same drug once discussed in general terms now requires scrutiny regarding its association with osteonecrosis of the jaw—a condition that has prompted legal settlements. For individuals in Pennsylvania, understanding the statute of limitations for filing a Fosamax-related claim becomes a practical extension of this shift, moving from passive health awareness to active legal and occupational risk assessment.

Fosamax and Osteonecrosis of the Jaw: A Medical Overview

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients may experience recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adverse reactions profile of Fosamax 70 mg once weekly was similar to that of Fosamax 10 mg daily in a one-year study (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In clinical studies of osteoporosis and Paget's disease, adverse events in patients taking Fosamax 40 mg/day for 3-12 months were similar to those in postmenopausal women treated with Fosamax 10 mg/day, though there was an increased incidence of upper gastrointestinal adverse reactions at the higher dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Statute of Limitations for Fosamax Claims in Pennsylvania

For patients in Pennsylvania who have developed ONJ after using Fosamax, the statute of limitations is a critical legal consideration. The statute of limitations for personal injury claims in Pennsylvania is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that affected patients must file any legal claim within two years of becoming aware of their ONJ diagnosis and its potential link to Fosamax use. The timeline between exposure to Fosamax and documented harm can vary, as ONJ symptoms may appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability underscores the importance of prompt medical evaluation and documentation of symptoms. Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer regarding the risk of ONJ. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, patients may argue that the warnings were insufficient to alert them to the specific risk, particularly given the variable onset of symptoms and the association with dental procedures. The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), which could be relevant for patients who used Fosamax for extended periods. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the timing of their ONJ diagnosis, the duration of Fosamax use, and any dental procedures that may have contributed to the condition. The statute of limitations in Pennsylvania requires timely action, and delays in filing could bar recovery. Medical records documenting the diagnosis of ONJ, the timeline of Fosamax use, and any associated dental procedures will be essential evidence. Additionally, patients should be aware that settlement amounts in such cases can vary widely based on the severity of the injury, the strength of the evidence linking Fosamax to the ONJ, and the specific legal arguments regarding the adequacy of warnings. In summary, Fosamax use is associated with a risk of ONJ, with onset of symptoms ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures and longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For Pennsylvania patients, the statute of limitations for filing a claim is generally two years from discovery of the injury. Settlement considerations hinge on the adequacy of warnings and the specific circumstances of each case. Patients should seek both medical and legal advice promptly to protect their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including those related to Fosamax and osteonecrosis of the jaw, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means affected patients must file their claim within two years of becoming aware of their ONJ diagnosis and its potential link to Fosamax use.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.